Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-06-27 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 特一药业集团股份有限公司 dated June 2022. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. There is no indication that this is a financial report, earnings release, or meeting minutes. Instead, it is a governance document outlining the internal rules and regulations of the company. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the bylaws, not just an announcement or summary.
2022-06-27 Chinese
国浩律师（深圳）事务所关于特一药业集团股份有限公司2022年第一次临时股东大会的法律意见书20220627
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the convening and procedures of a company's 2022 first extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholder meeting, including election of directors and supervisors. The document is not a report of financial results or management discussion, but a legal certification of the meeting's compliance with laws and company bylaws. It is not an announcement of voting results per se, but a legal opinion on the meeting's legality. Given the content and purpose, this fits best under Regulatory Filings (RNS) as a legal compliance document rather than a direct report or announcement category.
2022-06-27 Chinese
股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as "特一药业集团股份有限公司 股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting of Te Yi Pharmaceutical Group Co., Ltd." It details the rules, procedures, and governance related to the conduct of shareholders' meetings, including the convening, proposal submission, voting, resolutions, and authorization of the board by the shareholders' meeting. There is no financial data, earnings information, or audit content. It is not a report of results or a notice of voting results but a governance document outlining internal rules for shareholder meetings. This fits the definition of Governance Information (CGR), which covers the company's internal rules and governance practices. The document length is substantial (9646 characters), indicating it is the full rules document, not a brief announcement or summary. Therefore, the appropriate classification is CGR with high confidence.
2022-06-27 Chinese
关于第五届监事会第一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resolutions passed at the first meeting of the fifth Supervisory Board of the company. It includes election of the Supervisory Board chairman, approval of amendments to the company bylaws, and approval of the Supervisory Board remuneration plan. The document contains voting results and details about the elected chairman. It does not contain financial statements or financial performance data. It is a formal announcement of board/management changes and related governance matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or a notice of report publication, so it is not RPA or RNS.
2022-06-27 Chinese
关于完成监事会换届选举及部分监事届满离任的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the completion of the supervisory board (监事会) re-election and the departure of some supervisors due to term expiration. It details the election results, the new members' qualifications, and expresses gratitude to the departing supervisor. There is no financial data, no discussion of financial results, no mention of annual or interim reports, no audit information, no legal proceedings, no capital changes, and no voting results from a general meeting. The content focuses on management/board changes specifically related to the supervisory board members. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 2606 characters, which is relatively short but contains substantive information about board changes, not just an announcement of a report publication or a regulatory filing. Hence, the classification is MANG with high confidence.
2022-06-27 Chinese
关于完成董事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the completion of the board of directors' re-election for 特一药业集团股份有限公司. It details the election of new board members, their qualifications, and the composition of the new board. There is no financial data, no mention of annual or quarterly reports, no audit information, and no other report types. The content clearly relates to changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a substantive announcement about board changes.
2022-06-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.